Oryn Therapeutics LLC

[On Demand]
Oryn Therapeutics is a clinical-stage company developing a new class of drug candidates, Orynotides. These proprietary drug candidates are engineered, stable, cyclic peptides with very low immunogenicity and toxicity. They modulate pathologic inflammation and have proven effective in animal models of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis and ulcerative colitis. They have proven effective in preclinical cancer models and augment natural host defense, functioning as host-directed anti-infectives against drug resistant pathogens.

Oryn's lead candidate, ORTD-1, is in a Phase 1b study as a subcutaneous treatment for rheumatoid arthritis, and Oryn has an open IND for an intravenous formulation of ORTD-1. IND-enabling work is underway for development of a second Orynotide for cancer treatment.

Oryn's strategy is to fund further development of its drug candidates and to seek strategic partners for selected product development programs.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
ORTD-1 for rheumatoid arthritis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chief Executive Officer
Oryn Therapeutics LLC